Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study

Table 4 Stratified analyses by age and sex

	Individuals, n	Person-years	CRC diagnoses, n	IR, per 10,000 person-year	Crude			Adjusted^a
	Individuals, n	Person-years	CRC diagnoses, n	IR, per 10,000 person-year	HR	95% CI	P value	HR	95% CI	P value
Age
18–50
Non-users	49,240	508,989	441	8.66	1			1
Users	4924	51,026	30	5.88	0.83	0.49–1.41	0.497	0.81	0.47–1.40	0.450
>50
Non-users	101,750	676,536	1251	18.49	1			1
Users	10,175	69,177	97	14.02	0.75	0.61–0.93	0.007	0.75	0.61–0.93	0.008
Sex
Male
Non-users	81,960	580,524	810	13.95	1			1
Users	8196	59,044	63	10.67	0.75	0.58–0.97	0.031	0.75	0.57–0.97	0.031
Female
Non-users	86,210	605,001	621	10.26	1			1
Users	8621	61,159	49	8.01	0.77	0.58–1.03	0.083	0.75	0.56–1.02	0.063

CRC colorectal cancer, IR incidence rate, HR hazard ratio, CI confidence intervals, COPD chronic obstructive pulmonary disease, IBD inflammatory bowel disease, CCI Charlson Comorbidity Index score
^aAdjusted for age at index, sex, education, birth country, income, history of inflammatory bowel disease, COPD, obesity, outpatient visits, history of colonoscopy, use of aspirin, use of statin, and CCI

ISSN: 1741-7015